ArticleFrontiers in nephrology2025
Case Report: Fruquintinib-induced hyperbilirubinemia: a rare cause of dialyzer filter discoloration in a patient undergoing long-term dialysis.
Article in Frontiers in nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of a 55-year-old male patient with a medical history of cardiorenal syndrome and rectosigmoid colon adenocarcinoma, who started dialysis five years prior to presenting with unusual yellow discoloration of his dialyzer filter during his regular dialysis session. Following a regimen of standard chemotherapy, the patient was initiated on fruquintinib, 5 mg daily for 21 days, as an alternative treatment due to the intolerability of previous agents and failure of malignancy to respond. Shortly after starting fruquintinib, the patient developed hyperbilirubinemia and experienced significant yellow discoloration of the dialysis filter-a phenomenon not previously documented in association with this medication. The absence of dialyzer discoloration during five years of dialysis highlights the temporal relationship between the introduction of fruquintinib and the onset of filter discoloration. [removed some sentence] This case highlights the need for heightened awareness of potential adverse effects of fruquintinib, potentially detectable in patients undergoing dialysis, and aims to contribute to the growing body of literature on the medication's safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.